Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NASDAQ:AYTU NASDAQ:MRKR NASDAQ:MTVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.92-3.9%$6.07$7.96▼$24.15$24.81M0.6315,685 shs88,981 shsAYTUAytu BioPharma$2.19+2.8%$2.52$1.46▼$3.07$23.51M0.2855,034 shs20,561 shsMRKRMarker Therapeutics$1.40-2.1%$1.44$0.81▼$4.07$23.34M1.4364,565 shs63,234 shsMTVAMetaVia$3.85+34.1%$1.48$0.97▼$19.03$14.82M0.597.73 million shs40.20 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+6.00%-1.92%-18.47%-48.80%+53.75%AYTUAytu BioPharma+2.82%0.00%-15.77%-4.78%+8.42%MRKRMarker Therapeutics-2.10%-1.41%-9.09%-3.45%+27.27%MTVAMetaVia+34.15%+246.85%+139.13%+148.39%-60.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.92-3.9%$6.07$7.96▼$24.15$24.81M0.6315,685 shs88,981 shsAYTUAytu BioPharma$2.19+2.8%$2.52$1.46▼$3.07$23.51M0.2855,034 shs20,561 shsMRKRMarker Therapeutics$1.40-2.1%$1.44$0.81▼$4.07$23.34M1.4364,565 shs63,234 shsMTVAMetaVia$3.85+34.1%$1.48$0.97▼$19.03$14.82M0.597.73 million shs40.20 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+6.00%-1.92%-18.47%-48.80%+53.75%AYTUAytu BioPharma+2.82%0.00%-15.77%-4.78%+8.42%MRKRMarker Therapeutics-2.10%-1.41%-9.09%-3.45%+27.27%MTVAMetaVia+34.15%+246.85%+139.13%+148.39%-60.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AAYTUAytu BioPharma 2.40Hold$9.33326.18% UpsideMRKRMarker Therapeutics 2.25Hold$10.00614.29% UpsideMTVAMetaVia 2.00Hold$20.00419.48% UpsideCurrent Analyst Ratings BreakdownLatest MTVA, ALVR, AYTU, and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026MRKRMarker Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026MTVAMetaVia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.005/11/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/24/2026MTVAMetaVia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026AYTUAytu BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026MRKRMarker Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026MTVAMetaVia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $20.003/2/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AAYTUAytu BioPharma$56.60M0.42$0.39 per share5.67$3.27 per share0.67MRKRMarker Therapeutics$3.55M6.57N/AN/A$0.83 per share1.69MTVAMetaViaN/AN/AN/AN/A$1.76 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/AAYTUAytu BioPharma-$13.56M-$4.58N/A7.30N/A-60.17%-69.93%-13.25%N/AMRKRMarker Therapeutics-$12.16M-$0.61N/AN/AN/A-343.03%-73.29%-59.70%N/AMTVAMetaVia-$12.97M-$5.19N/AN/AN/AN/A-172.92%-89.39%8/6/2026 (Estimated)Latest MTVA, ALVR, AYTU, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026MRKRMarker Therapeutics-$0.18-$0.16+$0.02-$0.16$0.78 million$0.75 million5/14/2026Q1 2026MTVAMetaVia-$0.76-$0.79-$0.03-$0.79N/AN/A5/13/2026Q3 2026AYTUAytu BioPharma-$0.4433-$0.53-$0.0867-$0.53$12.05 million$12.41 million3/18/2026Q4 2025MRKRMarker Therapeutics-$0.21-$0.04+$0.17-$0.04$0.68 million$1.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78AYTUAytu BioPharma0.271.121.00MRKRMarker TherapeuticsN/A4.798.39MTVAMetaViaN/A2.732.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%AYTUAytu BioPharma33.49%MRKRMarker Therapeutics22.39%MTVAMetaVia1.37%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%AYTUAytu BioPharma4.90%MRKRMarker Therapeutics5.70%MTVAMetaVia0.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionNo DataAYTUAytu BioPharma16010.73 million10.21 millionNot OptionableMRKRMarker Therapeutics6016.67 million15.72 millionNot OptionableMTVAMetaVia85.16 million5.12 millionN/AMTVA, ALVR, AYTU, and MRKR HeadlinesRecent News About These CompaniesWhy MetaVia Stock Is Surging On Friday?May 22 at 12:50 PM | benzinga.comMTVA: Multiple upcoming presentations to highlight DA-1726 and VanoglipelMay 21 at 6:34 PM | msn.comWhy MetaVia Stock Is Falling On Thursday?May 21 at 2:50 PM | benzinga.comMetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASHMay 20 at 8:00 AM | prnewswire.comMetaVia (MTVA) jumps 45.9% as traders react to ADA 2026 late-breaking poster newsMay 19, 2026 | quiverquant.comQMetaVia (NASDAQ:MTVA) Receives "Buy" Rating from HC WainwrightMay 19, 2026 | americanbankingnews.comMetaVia Showcases Key Cardiometabolic Data at ADA 2026May 18, 2026 | tipranks.comMetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific SessionsMay 18, 2026 | prnewswire.comMetaVia (MTVA) Stock Forecast & Price TargetMay 14, 2026 | investing.comMetaVia Highlights Strong DA-1726 Phase 1 Weight-Loss DataMay 14, 2026 | tipranks.comMetaVia Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 14, 2026 | prnewswire.comMetaVia to Present New DA-1726 Obesity Data at EASLMay 11, 2026 | tipranks.comMetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026May 11, 2026 | prnewswire.comMetaVia (MTVA) price target decreased by 71.04% to 19.72April 29, 2026 | msn.comMetaVia Stock Dividends | NASDAQ:MTVA | BenzingaApril 28, 2026 | benzinga.comMetaVia Inc.: MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of ObesityApril 10, 2026 | finanznachrichten.deMetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of ObesityApril 10, 2026 | prnewswire.comMetaVia (MTVA) price target decreased by 15.51% to 68.08April 9, 2026 | msn.comMetaVia Inc.April 7, 2026 | edition.cnn.comMTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026…March 31, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTVA, ALVR, AYTU, and MRKR Company DescriptionsAlloVir NASDAQ:ALVR$4.92 -0.20 (-3.91%) As of 05/22/2026AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Aytu BioPharma NASDAQ:AYTU$2.19 +0.06 (+2.82%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.19 0.00 (0.00%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Marker Therapeutics NASDAQ:MRKR$1.40 -0.03 (-2.10%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.42 +0.02 (+1.36%) As of 05/22/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.MetaVia NASDAQ:MTVA$3.85 +0.98 (+34.15%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.63 -0.22 (-5.82%) As of 05/22/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
